Voyager Therapeutics (VYGR) Gains from Sales and Divestitures (2014 - 2026)

Voyager Therapeutics has disclosed Gains from Sales and Divestitures across 12 years of filings, most recently posting $545015.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $545015.0, up 20.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $545015.0 (up 20.96% YoY), and the FY2025 annual result was $691107.0, up 34.12% from the prior year.
• Gains from Sales and Divestitures came in at $545015.0 for Q1 2026 at Voyager Therapeutics, down from $691107.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $691107.0 in Q4 2025 to a low of $312090.0 in Q1 2022.
• The 5-year median for Gains from Sales and Divestitures is $437245.0 (2023), against an average of $456780.5.
• Across the five-year window, Gains from Sales and Divestitures jumped 69.41% in 2022 and slipped 13.33% in 2024, its largest moves.
• Voyager Therapeutics' Gains from Sales and Divestitures stood at $436611.0 in 2022, then grew by 21.75% to $531560.0 in 2023, then declined by 3.06% to $515303.0 in 2024, then soared by 34.12% to $691107.0 in 2025, then retreated by 21.14% to $545015.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $545015.0 (Q1 2026), $691107.0 (Q4 2025), and $568331.0 (Q3 2025), per Business Quant data.